Efficacity and Safety of the Fluocinolone Acetonide Implant in Uveitic Macular Edema: A Real-Life Study from the French Uveitis Network
Purpose: To evaluate the safety and efficacy of the fluocinolone acetonide implant (FAi, Iluvien<sup>®</sup> Horus pharma, Nice, France) in non-infectious uveitic macular edema (UME) and to approach the predictive factors of treatment response. Methods: This retrospective, multicenter re...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/14/3/245 |
| _version_ | 1797240327081295872 |
|---|---|
| author | Matthieu Jabbour Laurent Kodjikian Alexandre Bourdin Marie-Bénédicte Rougier Yasmine Serrar Michel Weber Hélène Massé Driss Mazhar Sara Perez-Roustit Christophe Chiquet Marie Nöelle Delyfer Bahram Bodaghi Sara Touhami |
| author_facet | Matthieu Jabbour Laurent Kodjikian Alexandre Bourdin Marie-Bénédicte Rougier Yasmine Serrar Michel Weber Hélène Massé Driss Mazhar Sara Perez-Roustit Christophe Chiquet Marie Nöelle Delyfer Bahram Bodaghi Sara Touhami |
| author_sort | Matthieu Jabbour |
| collection | DOAJ |
| description | Purpose: To evaluate the safety and efficacy of the fluocinolone acetonide implant (FAi, Iluvien<sup>®</sup> Horus pharma, Nice, France) in non-infectious uveitic macular edema (UME) and to approach the predictive factors of treatment response. Methods: This retrospective, multicenter real-life study included patients with chronic non-infectious UME who received intravitreal FAi after at least two dexamethasone implants (DEXi). Results: Twenty-six eyes from 22 patients (73.1% of females) were included. The mean age was 60.4 ± 16 years. The mean follow-up was 11.4 ± 2 months. The mean baseline best-corrected visual acuity (BCVA) was 0.43 ± 0.36 LogMAR, improving significantly after 1, 3, 6 and 12 months (all <i>p</i> < 0.05 vs. baseline). The mean baseline central macular thickness (CMT) was 429 ± 110 μm, improving significantly after 1, 3, 6 and 12 months (all <i>p</i> < 0.05 vs. baseline). Five eyes (19.2%) developed ocular hypertension during the follow-up, requiring initiation or strengthening of intraocular pressure lowering medication. The majority of eyes (77%) did not require any rescue DEXi during the available 12-month follow-up. The resolution of UME after DEXi seemed to predict the anatomical response after FAi. The baseline presence of a disorganization of the inner retinal layers (DRIL) and hyperreflective foci (HRF) were both associated with a higher likelihood of requiring rescue DEXi injections. Conclusion: FAi implantation led to a significant BCVA and CMT improvement with a good safety profile over the 12-month follow-up. Predictive factors of treatment outcomes seem to include the anatomical response to DEXi and the presence of DRIL and HRF at baseline. |
| first_indexed | 2024-04-24T18:05:40Z |
| format | Article |
| id | doaj.art-2234e3f86ddf4c90acf870f34eb110ec |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-04-24T18:05:40Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-2234e3f86ddf4c90acf870f34eb110ec2024-03-27T13:50:03ZengMDPI AGJournal of Personalized Medicine2075-44262024-02-0114324510.3390/jpm14030245Efficacity and Safety of the Fluocinolone Acetonide Implant in Uveitic Macular Edema: A Real-Life Study from the French Uveitis NetworkMatthieu Jabbour0Laurent Kodjikian1Alexandre Bourdin2Marie-Bénédicte Rougier3Yasmine Serrar4Michel Weber5Hélène Massé6Driss Mazhar7Sara Perez-Roustit8Christophe Chiquet9Marie Nöelle Delyfer10Bahram Bodaghi11Sara Touhami12Department of Ophthalmology, Pitié Salpêtrière University Hospital, Sorbonne University, 75013 Paris, FranceDepartment of Ophthalmology, Hôpital Universitaire de la Croix-Rousse, Hospices Civils de Lyon, University Claude Bernard Lyon 1, 69004 Lyon, FranceDepartment of Ophthalmology, Pitié Salpêtrière University Hospital, Sorbonne University, 75013 Paris, FranceCHU Bordeaux, Service d’Ophtalmologie, 33000 Bordeaux, FranceDepartment of Ophthalmology, Hôpital Universitaire de la Croix-Rousse, Hospices Civils de Lyon, University Claude Bernard Lyon 1, 69004 Lyon, FranceCHU Nantes, Service d’Ophtalmologie, Nantes University, 1 Place Alexis Ricordeau, 44093 Nantes, FranceCHU Nantes, Service d’Ophtalmologie, Nantes University, 1 Place Alexis Ricordeau, 44093 Nantes, FranceCHU Nantes, Service d’Ophtalmologie, Nantes University, 1 Place Alexis Ricordeau, 44093 Nantes, FranceDepartment of Ophthalmology, Grenoble Alpes University, 38043 Grenoble, FranceDepartment of Ophthalmology, Grenoble Alpes University, 38043 Grenoble, FranceCHU Bordeaux, Service d’Ophtalmologie, 33000 Bordeaux, FranceDepartment of Ophthalmology, Pitié Salpêtrière University Hospital, Sorbonne University, 75013 Paris, FranceDepartment of Ophthalmology, Pitié Salpêtrière University Hospital, Sorbonne University, 75013 Paris, FrancePurpose: To evaluate the safety and efficacy of the fluocinolone acetonide implant (FAi, Iluvien<sup>®</sup> Horus pharma, Nice, France) in non-infectious uveitic macular edema (UME) and to approach the predictive factors of treatment response. Methods: This retrospective, multicenter real-life study included patients with chronic non-infectious UME who received intravitreal FAi after at least two dexamethasone implants (DEXi). Results: Twenty-six eyes from 22 patients (73.1% of females) were included. The mean age was 60.4 ± 16 years. The mean follow-up was 11.4 ± 2 months. The mean baseline best-corrected visual acuity (BCVA) was 0.43 ± 0.36 LogMAR, improving significantly after 1, 3, 6 and 12 months (all <i>p</i> < 0.05 vs. baseline). The mean baseline central macular thickness (CMT) was 429 ± 110 μm, improving significantly after 1, 3, 6 and 12 months (all <i>p</i> < 0.05 vs. baseline). Five eyes (19.2%) developed ocular hypertension during the follow-up, requiring initiation or strengthening of intraocular pressure lowering medication. The majority of eyes (77%) did not require any rescue DEXi during the available 12-month follow-up. The resolution of UME after DEXi seemed to predict the anatomical response after FAi. The baseline presence of a disorganization of the inner retinal layers (DRIL) and hyperreflective foci (HRF) were both associated with a higher likelihood of requiring rescue DEXi injections. Conclusion: FAi implantation led to a significant BCVA and CMT improvement with a good safety profile over the 12-month follow-up. Predictive factors of treatment outcomes seem to include the anatomical response to DEXi and the presence of DRIL and HRF at baseline.https://www.mdpi.com/2075-4426/14/3/245uveitic macular edemadexamethasonefluocinolone acetonide implantchronic non-infectious uveitispredictive factorDRIL |
| spellingShingle | Matthieu Jabbour Laurent Kodjikian Alexandre Bourdin Marie-Bénédicte Rougier Yasmine Serrar Michel Weber Hélène Massé Driss Mazhar Sara Perez-Roustit Christophe Chiquet Marie Nöelle Delyfer Bahram Bodaghi Sara Touhami Efficacity and Safety of the Fluocinolone Acetonide Implant in Uveitic Macular Edema: A Real-Life Study from the French Uveitis Network Journal of Personalized Medicine uveitic macular edema dexamethasone fluocinolone acetonide implant chronic non-infectious uveitis predictive factor DRIL |
| title | Efficacity and Safety of the Fluocinolone Acetonide Implant in Uveitic Macular Edema: A Real-Life Study from the French Uveitis Network |
| title_full | Efficacity and Safety of the Fluocinolone Acetonide Implant in Uveitic Macular Edema: A Real-Life Study from the French Uveitis Network |
| title_fullStr | Efficacity and Safety of the Fluocinolone Acetonide Implant in Uveitic Macular Edema: A Real-Life Study from the French Uveitis Network |
| title_full_unstemmed | Efficacity and Safety of the Fluocinolone Acetonide Implant in Uveitic Macular Edema: A Real-Life Study from the French Uveitis Network |
| title_short | Efficacity and Safety of the Fluocinolone Acetonide Implant in Uveitic Macular Edema: A Real-Life Study from the French Uveitis Network |
| title_sort | efficacity and safety of the fluocinolone acetonide implant in uveitic macular edema a real life study from the french uveitis network |
| topic | uveitic macular edema dexamethasone fluocinolone acetonide implant chronic non-infectious uveitis predictive factor DRIL |
| url | https://www.mdpi.com/2075-4426/14/3/245 |
| work_keys_str_mv | AT matthieujabbour efficacityandsafetyofthefluocinoloneacetonideimplantinuveiticmacularedemaareallifestudyfromthefrenchuveitisnetwork AT laurentkodjikian efficacityandsafetyofthefluocinoloneacetonideimplantinuveiticmacularedemaareallifestudyfromthefrenchuveitisnetwork AT alexandrebourdin efficacityandsafetyofthefluocinoloneacetonideimplantinuveiticmacularedemaareallifestudyfromthefrenchuveitisnetwork AT mariebenedicterougier efficacityandsafetyofthefluocinoloneacetonideimplantinuveiticmacularedemaareallifestudyfromthefrenchuveitisnetwork AT yasmineserrar efficacityandsafetyofthefluocinoloneacetonideimplantinuveiticmacularedemaareallifestudyfromthefrenchuveitisnetwork AT michelweber efficacityandsafetyofthefluocinoloneacetonideimplantinuveiticmacularedemaareallifestudyfromthefrenchuveitisnetwork AT helenemasse efficacityandsafetyofthefluocinoloneacetonideimplantinuveiticmacularedemaareallifestudyfromthefrenchuveitisnetwork AT drissmazhar efficacityandsafetyofthefluocinoloneacetonideimplantinuveiticmacularedemaareallifestudyfromthefrenchuveitisnetwork AT saraperezroustit efficacityandsafetyofthefluocinoloneacetonideimplantinuveiticmacularedemaareallifestudyfromthefrenchuveitisnetwork AT christophechiquet efficacityandsafetyofthefluocinoloneacetonideimplantinuveiticmacularedemaareallifestudyfromthefrenchuveitisnetwork AT marienoelledelyfer efficacityandsafetyofthefluocinoloneacetonideimplantinuveiticmacularedemaareallifestudyfromthefrenchuveitisnetwork AT bahrambodaghi efficacityandsafetyofthefluocinoloneacetonideimplantinuveiticmacularedemaareallifestudyfromthefrenchuveitisnetwork AT saratouhami efficacityandsafetyofthefluocinoloneacetonideimplantinuveiticmacularedemaareallifestudyfromthefrenchuveitisnetwork |